Hepatamine

Isoleucine, Leucine, Lysine Acetate, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alani


B. Braun Medical Inc.
Human Prescription Drug
NDC 0264-9371
Hepatamine also known as Isoleucine, Leucine, Lysine Acetate, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alani is a human prescription drug labeled by 'B. Braun Medical Inc.'. National Drug Code (NDC) number for Hepatamine is 0264-9371. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Hepatamine drug includes Alanine - .77 g/100mL Arginine - .6 g/100mL Cysteine Hydrochloride - .014 g/100mL Glycine - .9 g/100mL Histidine - .24 g/100mL Isoleucine - .9 g/100mL Leucine - 1.1 g/100mL Lysine Acetate - .61 g/100mL Methionine - .1 g/100mL Phenylalanine - .1 g/100mL and more. The currest status of Hepatamine drug is Active.

Drug Information:

Drug NDC: 0264-9371
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Hepatamine
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Isoleucine, Leucine, Lysine Acetate, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alani
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: B. Braun Medical Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection, Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ALANINE - .77 g/100mL
ARGININE - .6 g/100mL
CYSTEINE HYDROCHLORIDE - .014 g/100mL
GLYCINE - .9 g/100mL
HISTIDINE - .24 g/100mL
ISOLEUCINE - .9 g/100mL
LEUCINE - 1.1 g/100mL
LYSINE ACETATE - .61 g/100mL
METHIONINE - .1 g/100mL
PHENYLALANINE - .1 g/100mL
PHOSPHORIC ACID - .115 g/100mL
PROLINE - .8 g/100mL
SERINE - .5 g/100mL
THREONINE - .45 g/100mL
TRYPTOPHAN - .066 g/100mL
VALINE - .84 g/100mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 03 Aug, 1982
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 18 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA018676
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:B. Braun Medical Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:800929
800933
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000175780
M0000922
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:OF5P57N2ZX
94ZLA3W45F
ZT934N0X4W
TE7660XO1C
4QD397987E
04Y7590D77
GMW67QNF9C
TTL6G7LIWZ
AE28F7PNPL
47E5O17Y3R
E4GA8884NN
9DLQ4CIU6V
452VLY9402
2ZD004190S
8DUH1N11BX
HG18B9YRS7
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Amino Acid [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class CS:Amino Acids [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Amino Acid [EPC]
Amino Acids [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0264-9371-556 CARTON in 1 CASE (0264-9371-55) / 1 CONTAINER in 1 CARTON / 500 mL in 1 CONTAINER03 Aug, 1982N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.